AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00750386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC, I.V, 5 every 2 weeks
Study NCT02075502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower extremity ET
Description: catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
Study NCT02075502 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: peripheral open intervention
Description: revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
Study NCT02075502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral open intervention
Description: revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
Study NCT04893746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10-L
Description: Low dose: 2x1010 CFU/day
Study NCT04893746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 0x1010 CFU/day
Study NCT04893746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum TWK10-H
Description: High dose: 6x1010 CFU/day
Study NCT03958682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR smart wearing equipment combined with 4G + satellite information transmission system
Description: We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors.
Study NCT06207500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led Medication Reconciliation
Description: The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
Study NCT03052608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK-positive NSCL treatment
Study NCT03052608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: ALK-positive NSCL treatment
Study NCT02748798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFP
Description: Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
Study NCT02748798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF6
Description: Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
Study NCT02748798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 129Xe Small and Large Human Lung Coil
Description: The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
Study NCT02748798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3He Human Lung Coil
Description: The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
Study NCT03071159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Flash Libre glucose monitoring system
Description: glucose monitoring system with sensors
Study NCT00520832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: 20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
Study NCT02748798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFP and SF6 Human Lung Coil
Description: The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
Study NCT01933152 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Study NCT02522221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin is an oral vitamin K antagonist anticoagulant.
Study NCT02647762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 1 mg
Description: CF101 tablets, 1mg BID for 12 weeks
Study NCT02522221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tecarfarin
Description: Tecarfarin is an oral vitamin K antagonist anticoagulant
Study NCT01321580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Pronto 7
Description: non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
Study NCT02647762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2 mg
Description: CF101 tablets, 2 mg BID for 12 weeks
Study NCT02647762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 1mg BID for 12 weeks
Study NCT02647762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
Study NCT01808118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every other week
Study NCT01808118 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every other week
Study NCT04420871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg of Xeloda®
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
Study NCT04420871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg of capecitabine
Description: Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
Study NCT03940651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Patients will be randomized to type of anesthesia
Study NCT03940651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthetics
Description: Patients will be randomized to type of anesthesia
Study NCT01701583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
Study NCT03218852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone and cyclophosphamide
Description: Prednisone and cyclophosphamide are both administered to participants in this group.
Study NCT03218852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone alone
Description: Prednisone is administered to participants in this group.
Study NCT03712163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 1)
Description: Single dose Norketotifen
Study NCT03712163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 2)
Description: Single dose Norketotifen
Study NCT03712163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Cohort 3)
Description: Single dose Norketotifen
Study NCT03712163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen Oral Capsule (Multiple Dose Cohort)
Description: Multiple dose Norketotifen
Study NCT03712163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo
Study NCT02679274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intermittent intramuscular injections of saline (males and females).
Study NCT02306772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating A
Description: One radio-labelled tablet given to subjects
Study NCT02306772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05 Coating B
Description: One radio-labelled tablet given to subjects
Study NCT04116632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Single dose with varying frequency among groups
Study NCT04116632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT02679274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
Study NCT03757663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UV Counseling
Description: Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
Study NCT01734122 — intervention group
Intervention type: OTHER
Intervention: Questionnaires / Observational Assessments
Description: Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
Study NCT00530322 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy).
Study NCT00905879 — intervention group
Intervention type: DRUG
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
Study NCT01222338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V-5 immunitor
Description: once per day dosing for 2 months
Study NCT01222338 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: V-5 immunitor
Description: once per day dosing for 2 months
Study NCT00589888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20% @ 20cc/hour
Description: In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
Study NCT00589888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%@ 40cc/hour
Description: In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
Study NCT00589888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
Study NCT00589888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 32-gram oral fat load
Description: In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
Study NCT00589888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 64-gram oral fat load
Description: In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
Study NCT03089177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Garden Intervention
Description: The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year.
Study NCT01143350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bras A (EHPAD Training and stimulation)
Description: EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD.
Study NCT01143350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EHPAD Control
Description: EHPAD of the reference group, will have their habitual functioning
Study NCT03175393 — intervention group
Intervention type: DEVICE
Intervention: coronary angiography
Description: per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
Study NCT01150877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
Study NCT05663996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: locally applied to the skin
Description: Applying St John's wort oil locally on the knee three times a day for three weeks.
Study NCT05663996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: locally applied to the skin
Description: Applying olive oil locally on the knee three times a day for three weeks.
Study NCT03126136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nicom (TM)
Description: Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
Study NCT03382899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus Pembrolizumab
Study NCT03382899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Alone
Study NCT03382899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab Alone
Study NCT00711399 — intervention group
Intervention type: DEVICE
Intervention: PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies
Description: wheeze and cough detection in hospitalized patients.
Study NCT03800706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
Study NCT02110810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin suppository of 100 mg immediately afterwards while still under sedation
Study NCT02110810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2.6-g suppository of glycerin
Description: to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
Study NCT03613090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen-hydroxyapatite scaffold (Syn-Oss)
Description: The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
Study NCT03613090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Scaffold (Colla-Plug)
Description: Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
Study NCT00559052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIOKASE 16
Description: The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
Study NCT03827473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03827473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given per standard of care
Study NCT03827473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03827473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03827473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01044719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 2g TDS IV
Study NCT02102269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulderlift
Study NCT02724826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong therapy
Description: Medical qigong
Study NCT02724826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Regular exercise
Study NCT03079388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use-supplementary food
Description: Specially formulated supplementary food for pregnancy
Study NCT03079388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy-blend
Description: Standard of care for malnutrition in pregnancy in Sierra Leone
Study NCT03079388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
Description: Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
Study NCT03079388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
Description: Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
Study NCT03079388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide-treated mosquito net
Description: An insecticide-treated mosquito net at the time of enrollment into the study.
Study NCT03079388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: An insecticide-treated mosquito net at the time of enrollment into the study.